Summary & Overview
HCPCS J7628: Bitolterol Mesylate Inhalation Solution, Compounded
HCPCS Level II code J7628 denotes bitolterol mesylate inhalation solution as a compounded, concentrated product billed per milligram for administration through durable medical equipment. This code captures the medication component of inhalation therapy in settings where DME delivers nebulized or inhaled formulations. Nationally, accurate use of J7628 affects pharmaceutical billing, reimbursement for compounded inhalation products, and tracking of therapy utilization for respiratory conditions requiring inhaled bronchodilators.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for compounded inhalation solutions, common sites of service where billing with J7628 is applicable, and typical payer coverage considerations. The publication outlines benchmarks and policy-relevant items such as billing practice trends, documentation expectations for compounded inhalation products, and alignment with DME-based administration workflows.
This summary provides a national perspective for health system coders, billing managers, and compliance teams on proper designation of the medication component when documenting and submitting claims for compounded inhalation therapy using DME.
Billing Code Overview
HCPCS Level II code J7628 represents bitolterol mesylate, inhalation solution, compounded product, concentrated form, per milligram, intended for administration through durable medical equipment (DME). This code is used to bill for the compounded inhalation medication itself rather than device-only services.
-
Service type: Pharmaceutical administration via compounded inhalation solution
-
Typical site of service: Respiratory therapy settings where DME is used, including outpatient infusion centers, hospital outpatient departments, home health settings when DME is used, and other facilities employing durable medical equipment for inhalation therapy
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with chronic obstructive pulmonary disease (COPD) and intermittent bronchospasm presents for outpatient inhalation therapy because their usual commercial bronchodilator formulations are not tolerated due to preservative sensitivity. The clinician orders a compounded concentrated inhalation solution of bitolterol mesylate to be administered through the patient’s durable medical equipment (nebulizer) at home. The pharmacy compounds the medication per prescription and bills the drug using HCPCS Level II code J7628 on a per milligram basis. The clinical workflow includes a clinician evaluation and prescription, sterile compounding by the pharmacy, coordination with the DME supplier to deliver or set up the nebulizer, patient education on nebulizer technique, and follow-up assessment for bronchodilator response and adverse effects.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply to the billed J7628 service. |
22 |